Lilly divests low blood sugar rescue treatment for $500M as industry focuses on dealmaking
As all eyes are on Big Pharma earnings season this week to see what drugmakers are buying, Eli Lilly is selling.
The Indianapolis drugmaker announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
